Friday November 8, 2024

 08:00 - 08:55 Session 10 - Strengths and limitations of cardiovascular toxicity risk stratification tools

8:00-8:10

Case presentation

Rebeca Lorca

8:10-8:20

HFA-ICOS Score

Eduardo Zatarain

8:20-8:30

Hematopoietic Stem Cell Transplantation: risk stratification strategies

Alberto López-García

8:30-8:40

Mean dose to the heart vs. dosimetric analysis of cardiac substructures: which one should we use?

Raquel Ciérvide

8:40-8:55

Discussion. Take home messages

09:00 - 09:40 Session 11. The future of cardio-oncology.

9:00 - 09:15

9:15 - 9:30

CMR in cardio-oncology: overcoming challenges, seizing opportunities

Chiara Bucciarelli

09:45 - 10:25 Session 12 - Update on cancer and HF

9:45 - 09:55

Case presentation

Cristina Mitroi

9:55 - 10:05

SGLT2 Inhibitors: A Dual Role in HF an cardio-oncology

Angel Manuel Iniesta Manjavacas

10:05 - 10:15

The role of CPET to stratify HF risk

Alessandra Cuomo

10:15 - 10:25

Discussion. Take home messages

10:25 - 10:55

Break with Snacks

11:00 - 11:50 Session 13 - The cardio-oncologist's best friend for cancer treatment monitoring

11:00 - 11:10

Cardiac biomarkers: when and how

Daniela Cardinale

11:10 - 11:20

Strain and 3D echo: from theory to practice

Teresa López-Fernández

11:20 - 11:30

New evidence in the evaluation of early cardiotoxicity with CMR

Santo Dellegrottaglie

11:30 - 11:40

Is there a role for cardiac CT?

Belén Terol Espinosa de los Monteros

11:40 - 11:50

Discussion. Take home messages

11:55 - 12:40 Session 14 - Intersecting cancer, inflammation and cardio-oncology: where do we stand?

11:55-12:05

Case presentation

Cristina Contreras

12:05-12:15

The emerging role of GLP-1 in modulating inflammation and cardiometabolic health.

Almudena Castro Conde

12:15-12:25

Exercise prescription in patients with cancer

Felipe Isidro Donate

12:25-12:40

Discussion. Take home messages

12:45 - 13:45 Session 15 - Understanding cardiovascular health in women with cancer 

Case presentation

Mª . Teresa Lozano Palencia

Impact of Cancer Therapies on Women's Hearts

Lucía González Cortijo

Optimizing CV risk factor control: a multidisciplinary approach

Regina Dalmau

How to assess and address residual risk

Clara Bonanad Lozano

Discussion. Take home messages

 13:40 - 14:15 Session 16 - How to organise a cardio-oncology programme. SEC-SEOM-SEOR-SEHH joint session 

13:40-13:55

Multidisciplinary collaboration in cancer management: When, Why and How?

Javier de Castro

SEC excelente in cardio-oncology:  objectives and structure

Teresa López-Fernández, Pedro Moliner

14:00-14:15

Discussion. Take home messages

14:15

CLOSING REMARKS